This post was originally published on this site A Phase 2 clinical trial of WP1220, a potential topical treatment of cutaneous T-cell lymphoma (CTCL) lesions, has reached full patient enrollment. Developed by Moleculin Biotech, WP1220 is an inhibitor of phospho (p)-STAT3, the activated form of a transcription factor key for cancer cell growth and survival.…
This post was originally published on this site Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the independent data monitoring committee of the PHOCUS Phase 3 trial reported. Based on these findings, the committee is…
This post was originally published on this site The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The combo is intended for people whose tumors cannot be removed by surgery (unresectable), are locally advanced or…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of metastatic castration-resistant prostate cancer (mCRPC). CCW702 is a bispecific antibody, acting as a bridge between cancer and…
This post was originally published on this site Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies…
This post was originally published on this site Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men with prostate cancer. Investigators from the DKFZ and Heidelberg University Clinic have been working on the development…
This post was originally published on this site The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with a gynecologic oncology expert. The OVATION 2 trial (NCT03393884) is enrolling at 34 sites across the U.S. It…
This post was originally published on this site GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase 2 trial, with the trial meeting its primary goal. Findings from the open-label DREAMM-2 study (NCT03525678) — which is assessing the treatment as a fourth-line…
This post was originally published on this site A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five years, the funds will support research to be conducted by the Pelotonia Institute for Immuno-Oncology (PIIO) at the…
This post was originally published on this site The United States Preventive Services Task Force (USPSTF) has revised their recommendations on testing for cancer-associated BRCA1/2 mutations in women, suggesting risk assessment only in those with a personal or family history of cancers associated with these mutations. These guidelines were published in the journal JAMA in a…
